 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, the Company, we, or our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and TriclonicsTM, today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology ASCO 2021 Gastrointestinal Cancers Symposium ASCO GI annual meeting being held virtually from January 15-17, 2021. 